Eluvia's sustained drug release leads to better clinical outcomes
96.1% Primary Patency at 12 Months
The Eluvia Drug-Eluting Stent System demonstrated an unprecedented 96.1% primary patency at 12 months, the highest reported in comparable SFA clinical trials.
Hear Prof. Müller-Hülsbeck share his analysis of Eluvia’s MAJESTIC Clinical Trial.
Get a firsthand look at the SFA stent design behind the data. The Eluvia Vascular Stent, with SUSTEND drug-delivery technology is designed to deliver paclitaxel when restenosis is most likely to occur.